Expert Interview
Another Look: Evaluating Xenon Pharmaceuticals’ Phase 3 X-TOLE2 and the 48-Month Outcomes Data of Azetukalner in Focal Onset Seizures, Presented at AAN 2026
Ticker(s): XENEInstitution: Columbia University
- Neurologist at Columbia University Irving Medical Center
- Manages hundreds of patients with epilepsy annually
- Research focuses on identifying genetic contributions to human health and disease with a focus on epilepsy, incorporating expertise in genetic epidemiology, human translational neuroscience, animal models, and imaging
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
